Conclusions
Currently, with the advent of targeted treatment and immunotherapy, identifying molecular subtypes may be of benefit for several cancer types. Immunotherapy, by ipilimumab, a fourth-line treatment, induced a complete and durable response after recurrence and progression on chemoradiotherapy and two BRAF inhibitors. Moreover this patient had clinical benefit with paclitaxel-carboplatin on what was perceived as an undifferentiated carcinoma, which became resistant when transformed to a S100-positive melanoma.
In conclusion, molecular screening in the primary biopsy and re-biopsy of the recurrence may be of clinical value in CUP, where evaluations with a broad spectrum of immunohistochemical and molecular analyses are necessary.
Acknowledgements
We thank the patient who generously provided consent to publish her medical history to help other patients.
Funding
There was no funding for writing this article.
Availability of data and materials
All data are available in the electronic medical records of our hospital, accessible to the treating medical doctors.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
J Med Case Reports. 2017;11(82) © 2017 BioMed Central, Ltd.
Comments